Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials. Therapeutic options in response to the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Drug discovery 2020-03, Vol.19 (3), p.149-150
Hauptverfasser:	Li, Guangdi, De Clercq, Erik
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Monophosphate - analogs & derivatives Adenosine Monophosphate - therapeutic use Alanine - analogs & derivatives Alanine - therapeutic use Antiviral agents Antiviral Agents - therapeutic use Betacoronavirus - drug effects Betacoronavirus - genetics Betacoronavirus - pathogenicity Clinical trials Comment Coronavirus Infections - drug therapy Coronaviruses COVID-19 Drug Repositioning Drug targeting Genetic aspects Hepatitis B - drug therapy Hepatitis C - drug therapy HIV Infections - drug therapy Humans Influenza, Human - drug therapy Interferon-alpha - pharmacology Interferon-alpha - therapeutic use Middle East Respiratory Syndrome Coronavirus - drug effects Middle East Respiratory Syndrome Coronavirus - genetics Middle East Respiratory Syndrome Coronavirus - pathogenicity Nucleosides - pharmacology Nucleosides - therapeutic use Pharmacology, Experimental Physiological aspects Pneumonia, Viral - drug therapy Polyethylene Glycols - pharmacology Polyethylene Glycols - therapeutic use Protease Inhibitors - pharmacology Protease Inhibitors - therapeutic use Recombinant Proteins - pharmacology Recombinant Proteins - therapeutic use SARS Virus - drug effects SARS Virus - genetics SARS Virus - pathogenicity SARS-CoV-2 Spike Glycoprotein, Coronavirus - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials. Therapeutic options in response to the 2019-nCoV outbreak are urgently needed. Here, we discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials.
ISSN:	1474-1776 1474-1784
DOI:	10.1038/d41573-020-00016-0